A vaccine to protect against Staphylococcus aureus infections
A multivalent vaccine for Staphylococcus aureus
This study is working on a new vaccine made from tiny particles to help protect people from infections caused by Staphylococcus aureus, especially the tough-to-treat MRSA, by boosting the body's immune response against the harmful effects of the bacteria.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11207159 on NIH RePORTER |
What this research studies
This research focuses on developing a nanoparticle vaccine designed to protect against infections caused by Staphylococcus aureus, particularly methicillin-resistant strains (MRSA). The vaccine aims to elicit a strong immune response by targeting specific virulence factors of the bacteria, which are responsible for severe infections such as skin infections, pneumonia, and sepsis. By using a novel platform based on human hepatitis core antigens, the researchers hope to create a multivalent vaccine that can neutralize multiple harmful toxins produced by the bacteria. This approach has shown promise in preclinical models, indicating potential effectiveness in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for MRSA infections, such as patients with compromised immune systems or those undergoing certain medical procedures.
Not a fit: Patients who are not at risk for Staphylococcus aureus infections or those who have already been vaccinated against MRSA may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a highly effective vaccine that significantly reduces the incidence of MRSA infections in patients.
How similar studies have performed: Previous research has demonstrated success in developing vaccines targeting similar bacterial infections, indicating a promising avenue for this approach.
Where this research is happening
Ann Arbor, United States
- Veterans Health Administration — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Oscherwitz, Jon — Veterans Health Administration
- Study coordinator: Oscherwitz, Jon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.